This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Louise Glassner Cohen, PharmD; Shelley Chesley, MD; Linda Eugenio, PharmD; James G. Flood, PhD; Judith Fisch, MD; Donald C. Goff, MD

Arch Intern Med. 1996;156(6):675-677.

Abstract
Clozapine, used in the treatment of patients with schizophrenia resistant to other neuroleptic medication, is metabolized by the hepatic microsomal system to demethyl-clozapine and clozapine-N-oxide. Changes in clozapine serum concentrations have been documented after initiation of therapy with medications known to induce or inhibit liver microsomal enzymes. These interactions are of clinical importance when diminished efficacy or increased toxic effects of clozapine therapy occur. A 34-year-old schizophrenic man had increased clozapine serum concentrations, leukocytosis, and adverse effects as a result of concomitant erythromycin therapy given for a suspected lower respiratory tract infection. Symptoms included somnolence, difficulty in coordination and ambulation, slurred speech, disorientation, and incontinence. The symptoms resolved after treatment with clozapine and erythromycin were discontinued, and treatment with clozapine was gradually resumed.

(Arch Intern Med. 1996;156:675-677)

Author Affiliations
From the Department of Pharmacy Practice, Bouve College of Pharmacy, Northeastern University, Boston, Mass (Dr Cohen); Departments of Pharmacy (Dr Cohen), Clinical Chemistry (Dr Flood), and Medicine (Dr Fisch) and Psychiatry Service (Drs Chesley and Goff), Massachusetts General Hospital, Boston; and Division of Pharmacy Practice, Massachusetts College of Pharmacy, and Department of Pharmacy, Lahey Clinic, Burlington, Mass (Dr Eugenio).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interindividual Variation in Relative CYP1A2/3A4 Phenotype Influences Susceptibility of Clozapine Oxidation to Cytochrome P450-Specific Inhibition in Human Hepatic Microsomes
Zhang et al.
Drug Metab. Dispos. 2008;36:2547-2555.
ABSTRACT | FULL TEXT  

Metabolism of Clozapine by cDNA-Expressed Human Cytochrome P450 Enzymes
Linnet and Olesen
Drug Metab. Dispos. 1997;25:1379-1382.
ABSTRACT | FULL TEXT